Ligand-triggered resistance to molecular targeted drugs in lung cancer: Roles of hepatocyte growth factor and epidermal growth factor receptor ligands

Cancer Science

Volumn 103, Issue 7, 2012, Pages 1189-1194

  Yano, Seiji ^a   Takeuchi, Shinji ^a   Nakagawa, Takayuki ^b   Yamada, Tadaaki ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; INTERLEUKIN 1; LIGAND; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SCATTER FACTOR; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; CANCER CELL; CANCER CELL CULTURE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FIBROBLAST; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG CANCER; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; WILD TYPE;

DRUG RESISTANCE, NEOPLASM; HEPATOCYTE GROWTH FACTOR; HUMANS; LIGANDS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84863304804     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02279.x     Document Type: Review

References (62)

1. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
2. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
3. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-6.
4. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-8.
5. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-8.
6. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-703.
7. Jackman D, Pao W, Riely GJ et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010; 28: 357-60.
8. Shaw AT, Yeap BY, Solomon BJ et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011; 12: 1004-12.
9. Pao W, Chmielecki J Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010; 10: 760-74.
10. Engelman JA, Jänne PA Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008; 14: 2895-9.
11. Yano S, Wang W, Li Q et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma cells with EGF receptor mutations. Cancer Res 2008; 68: 9479-87.
12. McCoy MS, Toole JJ, Cunningham JM, Chang EH, Lowy DR, Weinberg RA Characterization of a human colon/lung carcinoma oncogene. Nature 1983; 302: 79-81.
13. Hammerman PS, Sos ML, Ramos AH et al. Mutations in the DDR kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011; 1: 78-89.
14. Bergethon K, Shaw AT, Ignatius Ou SH et al. ros1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012; 30: 863-70.
15. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003; 21: 2237-46.
16. Herbst RS, Heymach JV, Lippman SM Lung cancer. N Engl J Med 2008; 359: 1367-80.
17. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-8.
18. Ohe Y, Ohashi Y, Kubota K et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007; 18: 317-23.
19. Inamura K, Takeuchi K, Togashi Y et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009; 22: 508-15.
20. Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-92.
21. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
22. Choi YL, Soda M, Yamashita Y et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363: 1734-9.
23. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-43.
24. Katayama R, Khan TM, Benes C et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA 2011; 108: 7535-40.
25. Yamamoto C, Basaki Y, Kawahara A et al. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res 2010; 70: 8715-25.
26. Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75ra26.
27. Faber A, Corcoran RB, Ebi H et al. BIM expression in treatment naïve cancers predicts responsiveness to kinase inhibitors. Cancer Discov 2011; 1: 352-65.
28. Nakamura T, Nishizawa T, Hagiya M et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989; 342: 440-3.
29. Nakamura T, Sakai K, Nakamura T, Matsumoto K Hepatocyte growth factor twenty years on: much more than a growth factor. J Gastroenterol Hepatol 2011; 26 (Suppl 1): 188-202.
30. Harvey P, Warn A, Newman P, Perry LJ, Ball RY, Warn RM Immunoreactivity for hepatocyte growth factor/scatter factor and its receptor, met, in human lung carcinomas and malignant mesotheliomas. J Pathol 1996; 180: 389-94.
31. Olivero M, Rizzo M, Madeddu R et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 1996; 74: 1862-8.
32. Tokunou M, Niki T, Eguchi K et al. c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma. Am J Pathol 2001; 158: 1451-63.
33. Stabile LP, Lyker JS, Land SR, Dacic S, Zamboni BA, Siegfried JM Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer. Carcinogenesis 2006; 27: 1547-55.
34. Nakamura T, Matsumoto K, Kiritoshi A, Tano Y, Nakamura T Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res 1997; 57: 3305-13.
35. Grotegut S, von Schweinitz D, Christofori G, Lehembre F Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. EMBO J 2006; 25: 3534-45.
36. Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, Nakamura T HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 2000; 60: 6737-43.
37. Rong S, Segal S, Anver M, Resau JH, Vande Woude GF Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci USA 1994; 91: 4731-5.
38. Ichimura E, Maeshima A, Nakajima T, Nakamura T Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 1996; 87: 1063-9.
39. Siegfried JM, Weissfeld LA, Singh-Kaw P, Weyant RJ, Testa JR, Landreneau RJ Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res 1997; 57: 433-9.
40. Wang W, Li Q, Yamada T et al. Crosstalk to stromal fibroblasts induces resistance of lung cancer to EGFR tyrosine kinase inhibitors. Clin Cancer Res 2009; 15: 6630-8.
41. Turke AB, Zejnullahu K, Wu YL et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010; 17: 77-88.
42. Yano S, Yamada T, Takeuchi S et al. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 2011; 6: 2011-7.
43. Suda K, Murakami I, Katayama T et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 2010; 16: 5489-98.
44. Onitsuka T, Uramoto H, Nose N et al. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer 2010; 68: 198-203.
45. Yasuda H, Kobayashi S, Costa DB EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol 2012; 13: e23-31.
46. Yamada T, Matsumoto K, Wang W et al. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clin Cancer Res 2010; 16: 174-83.
47. Wang W, Li Q, Takeuchi S et al. E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells. Clin Cancer Res 2012; 18: 1663-71.
48. Guix M, Faber AC, Wang SE et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. Clin Invest 2008; 118: 2609-19.
49. Yano S, Nakataki E, Ohtsuka S et al. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncol Res 2005; 15: 107-11.
50. Sharma SV, Lee DY, Li B et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141: 69-80.
51. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 1525-31.
52. Pirker R, Pereira JR, von Pawel J et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012; 13: 33-42.
53. Yamada T, Takeuchi S, Kita K et al. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. J Thorac Oncol 2012; 7: 272-80.
54. Sasaki T, Okuda K, Zheng W et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 2010; 70: 10038-43.
55. Sasaki T, Koivunen J, Ogino A et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011; 71: 6051-60.
56. Heuckmann JM, Hölzel M, Sos ML et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res 2011; 17: 7394-401.
57. Katayama R, Shaw AT, Khan TM et al. Mechanisms of Acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012; 4: 120ra17.
58. Yamada T, Takeuchi S, Nakade J et al. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells. Clin Cancer Res, in press.
59. Sakamoto H, Tsukaguchi T, Hiroshima S et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011; 19: 679-90.
60. Okamoto W, Okamoto I, Tanaka K et al. TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. Mol Cancer Ther 2010; 9: 2785-92.
61. Jin H, Yang R, Zheng Z et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008; 68: 4360-8.
62. Donev IS, Wang W, Yamada T et al. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res 2011; 17: 2260-9.